

# HOUSE BILL 1119

J2

0lr2532

---

By: **Delegate Shetty**

Introduced and read first time: February 6, 2020

Assigned to: Health and Government Operations

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Pharmacists – Required Notification and Authorized Substitution – Lower-Cost**  
3 **Brand Name Drug or Device Product**

4 FOR the purpose of requiring a pharmacist, or the pharmacist’s designee who is under  
5 certain supervision, to inform a certain consumer of the availability of certain  
6 therapeutically equivalent brand name drugs and the cost difference between the  
7 therapeutically equivalent drug and a certain prescribed brand name drug;  
8 authorizing a pharmacist to substitute a therapeutically equivalent brand name  
9 drug or device product for a certain prescribed drug or device product under certain  
10 circumstances; requiring a pharmacist to provide certain notice to a patient and  
11 make and keep a certain record if a certain therapeutically equivalent brand name  
12 drug or device is substituted for a certain drug or device product; making stylistic  
13 and conforming changes; and generally relating to pharmacists and drugs and device  
14 products.

15 BY repealing and reenacting, with amendments,  
16 Article – Health Occupations  
17 Section 12–504  
18 Annotated Code of Maryland  
19 (2014 Replacement Volume and 2019 Supplement)

20 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
21 That the Laws of Maryland read as follows:

22 **Article – Health Occupations**

23 12–504.

24 (a) In this section, “brand name” means the proprietary name a manufacturer  
25 places on a drug or device product or its container.

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 (b) (1) Subject to the provisions of this subtitle, a pharmacist, or the  
2 pharmacist's designee, who is under the direct supervision of the pharmacist, shall inform  
3 a retail consumer to the best of the pharmacist's or the pharmacist's designee's knowledge  
4 of the availability of a generically equivalent drug, **A THERAPEUTICALLY EQUIVALENT**  
5 **BRAND NAME DRUG THAT IS LOWER IN COST THAN THE ORIGINALLY PRESCRIBED**  
6 **BRAND NAME DRUG**, or an interchangeable biological product and shall inform a retail  
7 consumer of the approximate cost difference as compared to the **ORIGINALLY**  
8 **PRESCRIBED** brand name drug.

9 (2) The Board shall adopt procedures for:

10 (i) A consumer to notify the Board when a pharmacist fails to  
11 provide the information required under paragraph (1) of this subsection; and

12 (ii) Advising a pharmacist to bring the pharmacist into compliance  
13 with the requirements of paragraph (1) of this subsection.

14 (3) Paragraph (1) of this subsection does not apply:

15 (i) To a prescription that is written for a generic drug or an  
16 interchangeable biological product;

17 (ii) When the authorized prescriber states expressly that the  
18 prescription is to be dispensed only as directed;

19 (iii) To a pharmacist who works in a pharmacy, whether centralized  
20 or decentralized, which primarily serves public or private institutional recipients; or

21 (iv) When the cost of the prescription is reimbursed by a third party  
22 payer, including medical assistance.

23 (c) The Board shall maintain a link on its [Web site] **WEBSITE** to the current lists  
24 of biological products determined by the United States Food and Drug Administration to  
25 be interchangeable with a specific biological product.

26 (d) A pharmacist may substitute a generically equivalent drug or device product,  
27 **A THERAPEUTICALLY EQUIVALENT BRAND NAME DRUG OR DEVICE PRODUCT**, or an  
28 interchangeable biological product, of the same dosage form and strength, for [any] **THE**  
29 brand name drug or device product **ORIGINALLY** prescribed, if:

30 (1) The authorized prescriber does not state expressly that the prescription  
31 is to be dispensed only as directed;

32 (2) The substitution is:

1 (i) Recognized in the United States Food and Drug Administration's  
2 current list of approved drug or device products with therapeutic equivalence evaluations;  
3 or

4 (ii) An interchangeable biological product for the brand name drug  
5 or device product **ORIGINALLY** prescribed; and

6 (3) The consumer is charged less for the substituted drug or device or  
7 interchangeable biological product than the price of the **ORIGINALLY PRESCRIBED** brand  
8 name drug or device.

9 (e) If a drug or device product or an interchangeable biological product is  
10 substituted under this section, the pharmacist shall:

11 (1) Notify the patient in writing that the drug or device product or  
12 interchangeable biological product dispensed is a generic equivalent of, **A BRAND NAME**  
13 **DRUG OR DEVICE PRODUCT THAT IS THERAPEUTICALLY EQUIVALENT TO**, or is  
14 interchangeable with the **ORIGINALLY** prescribed drug or device product; and

15 (2) Record on the prescription and keep a record of the name and  
16 manufacturer of the substituted drug or device product or interchangeable biological  
17 product.

18 (f) The Department may list any additional drug or device products that are  
19 determined by the Department to meet requirements that are adequate to assure product  
20 quality and therapeutic equivalence, after an opportunity for public comment as provided  
21 in Title 10, Subtitle 1 of the State Government Article.

22 (g) The Department may disqualify a drug or device product or an  
23 interchangeable biological product on the United States Food and Drug Administration's  
24 current list from being used in Maryland as a substitute if the Department determines that  
25 the drug or device or interchangeable biological product is therapeutically nonequivalent  
26 or not interchangeable, respectively, or has a negative physical or biological effect on the  
27 consumer of that drug or device product or interchangeable biological product:

28 (1) After providing an opportunity for public comment as provided in Title  
29 10, Subtitle 1 of the State Government Article; or

30 (2) Prior to providing an opportunity for public comment, if the  
31 Department believes that a particular generic drug or device product or interchangeable  
32 biological product constitutes an imminent danger to the public health, safety or welfare,  
33 and the Department:

34 (i) Provides an opportunity for public comment as provided in Title  
35 10, Subtitle 1 of the State Government Article within 30 days of disqualifying the drug or  
36 device product or interchangeable biological product; and

1 (ii) After providing an opportunity for public comment, determines  
2 whether the drug or device product or interchangeable biological product should remain  
3 disqualified.

4 (h) For a drug or device product or an interchangeable biological product that the  
5 Department has disqualified from being used in Maryland as a substitute under subsection  
6 (g) of this section, the Department shall provide an opportunity for public comment as  
7 provided in Title 10, Subtitle 1 of the State Government Article before reinstating the drug  
8 or device product or interchangeable biological product for use in Maryland as a substitute.

9 (i) A pharmacist who substitutes a drug or device product or an interchangeable  
10 biological product in compliance with this section incurs no greater liability in filling the  
11 prescription by dispensing the equivalent drug or device product or interchangeable  
12 biological product than would be incurred in filling the prescription by dispensing the  
13 **ORIGINALLY** prescribed brand name drug or device.

14 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
15 October 1, 2020.